| Pharmaceutical Information |
| Drug Name |
Bosutinib monohydrate |
| Drug ID |
BADD_D00287 |
| Description |
Bosutinib is a Bcr-Abl kinase inhibitor for the treatment of Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML). Compared to other tyrosine kinase inhibitors, it has a more favourable hematologic toxicity profile. FDA approved on September 4, 2012. |
| Indications and Usage |
Treatment of chronic, accelerated, or blast phase Philadelphia chromosome-positive (Ph+) chronic myelogenous leukemia (CML) with resistance or intolerance to prior therapy in adult patients. |
| Marketing Status |
approved |
| ATC Code |
L01EA04 |
| DrugBank ID |
DB06616
|
| KEGG ID |
D09728
|
| MeSH ID |
C471992
|
| PubChem ID |
11990828
|
| TTD Drug ID |
D0OB0F
|
| NDC Product Code |
0069-0135; 0069-0193; 0069-0136 |
| UNII |
844ZJE6I55
|
| Synonyms |
bosutinib | SKI606 | SKI-606 |
|
| Chemical Information |
| Molecular Formula |
C26H31Cl2N5O4 |
| CAS Registry Number |
918639-08-4 |
| SMILES |
CN1CCN(CC1)CCCOC2=C(C=C3C(=C2)N=CC(=C3NC4=CC(=C(C=C4Cl)Cl)OC)C#N)OC.O |
| Chemical Structure |
|
|
| ADRs Induced by Drug |
|
|
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
|
|
| ADR Term |
ADReCS ID |
ADR Frequency (FAERS)
|
ADR Severity Grade (FAERS)
|
ADR Severity Grade (CTCAE)
|
| Liver injury | 09.01.07.022; 12.01.17.012 | - | - | - | | Acute kidney injury | 20.01.03.016 | - | - | |
|
|
|
